Short answer: Canagliflozin has a half-life of about 10.6 to 13.1 hours. Levels peak 1 to 2 hours after a dose. People vary, so treat these as estimates.
Canagliflozin is an SGLT2 inhibitor: it makes the kidneys pass more sugar into the urine. It is sold as Invokana, a once-daily tablet for type 2 diabetes that is also approved to lower heart and kidney risks in some adults with diabetes.
Also known as: Invokana.
Invokana comes as 100 mg and 300 mg tablets.
The FDA Invokana label approves it, with diet and exercise, to improve blood sugar in adults and children 10 and older with type 2 diabetes; to lower the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes and heart disease; and to lower kidney and heart risks in adults with type 2 diabetes and diabetic kidney disease. The label dose is 100 mg once a day before the first meal; for blood sugar it may go to 300 mg if eGFR is 60 or above, and no higher than 200 mg below 60. It is not for type 1 diabetes, and is not started when eGFR is below 30.
The label warns about ketoacidosis (and says to stop it at least 3 days before surgery or long fasting if possible), dehydration, genital and urinary infections, and lower limb amputation: in the CANVAS trials amputations were more common on canagliflozin than placebo (5.9 vs 2.8 and 7.5 vs 4.2 per 1,000 patient-years), mostly of toes and the middle of the foot. See also empagliflozin and dapagliflozin.
The FDA Invokana label gives an apparent terminal half-life of 10.6 hours at 100 mg and 13.1 hours at 300 mg, with peak levels 1 to 2 hours after a dose and steady state after 4 to 5 days. Bioavailability is about 65%, and a high-fat meal did not change its pharmacokinetics.
Numbers shown are taken from the source above. Half-life varies from person to person.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator